Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 58

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 58
---
 Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and with an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in the money options, an expected life equal to the original ratio of expected life relative to the ten year contractual life multiplied times the remaining life as of the applicable revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our 2024 Form 10-K for the fiscal year ended December 31, 2024 and prior fiscal years.

Relationship Between Financial Performance Measures

The graphs below compare the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs, with (i) our cumulative TSR and (ii) our Net Income (Loss), in each case, for the fiscal years ended December 31, 2024 and 2023. TSR amounts reported in the graph assume an initial fixed investment of $100, and that all dividends, if any, were reinvested.

<div align='center'>42</div>

Equity Compensation Plan Information The following table summarizes securities available under our equity compensation plans as of December 31, 2024.

| Equity compensation plans approved by stockholders:      |     | (A) Number of     
 securities to be  
 issued upon       
 exercise          
 of outstanding    
 options, warrants 
 and rights        |           |     | (B) Weighted      
 average per       
 share exercise    
 price of          
 outstanding       
 options, warrants 
 and rights        |       |     |        (C) Number of 
           Securities 
            remaining 
            available 
         under equity 
         compensation 
     plans (excluding 
 securities reflected 
       in column (A)) |           |     |    |
|:---------------------------------------------------------|:----|:------------------|----------:|:----|:------------------|------:|:----|---------------------:|----------:|:----|---:|
| 2019 Equity Incentive Plan                               |     |                   | 1,073,120 |     | $                 |